Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;8(Suppl 2):S130-S132.
doi: 10.21037/tcr.2018.12.04.

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape

Vadim S Koshkin  1 , Arnab Basu  2 , Petros Grivas  3
Affiliations
Editorial

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape

Vadim S Koshkin et al. Transl Cancer Res. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Grivas has done consulting with Pfizer, EMD Serono, Astra Zeneca, Merck & Co., Bristol-Myers Squibb, Clovis Oncology, QED Therapeutics, Seattle Genetics, Foundation Medicine, Heron Therapeutics, Driver Inc. within a year from the submission, but unrelated to this Editorial. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8. 10.1200/JCO.2005.07.757 - DOI - PubMed
    1. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-4. 10.1016/S1470-2045(10)70275-8 - DOI - PubMed
    1. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191-9. 10.1200/JCO.2011.37.3571 - DOI - PMC - PubMed
    1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20. 10.1016/S0140-6736(16)00561-4 - DOI - PMC - PubMed